[go: up one dir, main page]

BR9910568A - Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos - Google Patents

Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Info

Publication number
BR9910568A
BR9910568A BR9910568-3A BR9910568A BR9910568A BR 9910568 A BR9910568 A BR 9910568A BR 9910568 A BR9910568 A BR 9910568A BR 9910568 A BR9910568 A BR 9910568A
Authority
BR
Brazil
Prior art keywords
agonist
csf receptor
receptor
selection process
receptor antibodies
Prior art date
Application number
BR9910568-3A
Other languages
English (en)
Inventor
Baofu Ni
Bill N C Sun
Cecily R Y Sun
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of BR9910568A publication Critical patent/BR9910568A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"ANTICORPOS AGONISTAS DE RECEPTOR DE G-CSF E PROCESSO DE SELEçãO PARA OS MESMOS"<D>. A invenção refere-se a moléculas agonistas que se ligam especificante a ou interagem com o receptor de G-CSF humano e dimerizam o receptor ou ativam a fosforilação de quinases associadas com o receptor para estimular a proliferação e a diferenciação celular. Tais moléculas agonistas incluem anticorpos monoclonais, ou fragmentos, homólogos ou análogos destas ou peptídeos ou compostos orgânicos. São descritos dois exemplos de anticorpos agonistas monoclonais de camundongo: mAb 163-93 e mAb174-74-11.
BR9910568-3A 1998-04-30 1999-04-30 Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos BR9910568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8357598P 1998-04-30 1998-04-30
PCT/US1999/009466 WO1999055735A1 (en) 1998-04-30 1999-04-30 G-csf receptor agonist antibodies and screening method therefor

Publications (1)

Publication Number Publication Date
BR9910568A true BR9910568A (pt) 2001-09-11

Family

ID=22179233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910568-3A BR9910568A (pt) 1998-04-30 1999-04-30 Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos

Country Status (12)

Country Link
EP (1) EP1073683B1 (pt)
JP (1) JP3979008B2 (pt)
KR (1) KR100479790B1 (pt)
CN (2) CN101070344A (pt)
AT (1) ATE314396T1 (pt)
AU (2) AU764653B2 (pt)
BR (1) BR9910568A (pt)
CA (1) CA2326755A1 (pt)
DE (1) DE69929183T2 (pt)
ES (1) ES2253887T3 (pt)
NZ (1) NZ507782A (pt)
WO (1) WO1999055735A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363931A4 (en) * 2001-02-01 2004-04-07 Tanox Inc METHOD FOR THE PRODUCTION AND IDENTIFICATION OF MONOCLONAL ANTIBODIES AGAINST A LARGE NUMBER OF HUMAN ANTIGENS
KR20090024243A (ko) 2006-06-08 2009-03-06 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
EP2154242B1 (en) * 2007-06-07 2016-01-06 Keiichi Fukuda Method of inducing differentiation into myocardial cells using g-csf
EP2236604B1 (en) 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
US9737612B2 (en) 2011-03-01 2017-08-22 Novo Nordisk A/S Antagonistic DR3 ligands
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
LT3284480T (lt) 2015-04-14 2025-08-11 Chugai Seiyaku Kabushiki Kaisha Farmacinė kompozicija, skirta atopinio dermatito profilaktikai ir (arba) gydymui, savo sudėtyje turinti il-31 antagonistą kaip veikliąją medžiagą
CN107810420B (zh) 2015-06-25 2020-08-14 豪夫迈·罗氏有限公司 用于测定抗体或配体结合和功能的基于细胞的测定
AU2020387034A1 (en) 2019-11-20 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131
CN114292843B (zh) * 2021-12-03 2023-07-21 中国科学院精密测量科学与技术创新研究院 一种基因兴奋剂的CRISPR/Cas12a检测体系及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AUPM375094A0 (en) * 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules and methods for assaying cytokine function
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
EP0859843A1 (en) * 1995-10-05 1998-08-26 G.D. Searle & Co. Novel g-csf receptor agonists

Also Published As

Publication number Publication date
AU764653B2 (en) 2003-08-28
EP1073683A4 (en) 2001-08-22
CN1326880C (zh) 2007-07-18
AU2003252863A1 (en) 2003-11-06
EP1073683B1 (en) 2005-12-28
NZ507782A (en) 2003-12-19
KR20010043112A (ko) 2001-05-25
CN101070344A (zh) 2007-11-14
ES2253887T3 (es) 2006-06-01
JP3979008B2 (ja) 2007-09-19
DE69929183T2 (de) 2006-08-24
CA2326755A1 (en) 1999-11-04
JP2002512782A (ja) 2002-05-08
EP1073683A1 (en) 2001-02-07
ATE314396T1 (de) 2006-01-15
AU3673299A (en) 1999-11-16
CN1298412A (zh) 2001-06-06
WO1999055735A1 (en) 1999-11-04
KR100479790B1 (ko) 2005-03-30
DE69929183D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
BR9910568A (pt) Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
AR055191A1 (es) Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
AR003431A1 (es) Peptidos compuestos que se ligan al receptor de trombopoietina.
AR005397A1 (es) Anticuerpo agonista monoclonal que se liga especificamente al receptor ob, un metodo para mejorar la proliferacion o diferenciacion in vitro de una celula que comprende un receptor ob, el uso de un anticuerpo agonista anti-receptor ob para la preparacion de una dosificacion fisiologicamente aceptable, y metodos para identificar un anticuerpo que se liga o activa al receptor ob que incrementa la proliferacion o diferenciacion de una celula
BR0316101A (pt) Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
CY1112101T1 (el) Νευροτροφικοι παραγοντες
BR9713914A (pt) Composto, uso do mesmo, composição farmacêutica, e processo para tratar um paciente sofrendo de um distúrbio que é susceptìvel a tratamento com um agonista da trombopoietina.
CA2395724A1 (en) NUCLEIC ACIDS, PROTEINS AND ANTIBODIES
BR9710357A (pt) Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
DE60224291D1 (de) System zur antikörperexpression und- synthese
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
EA200500647A1 (ru) Антитела, связывающие клеточные полипептиды ca 125/0772p, и способы их применения
SG170080A1 (en) Human monoclonal antibodies to o8e
EA200801732A1 (ru) Модуляторы ауроракиназы, способы их получения и их применение
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
Bhide et al. Collagen phagocytosis by fibroblasts is regulated by decorin
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
BR9806318A (pt) Polipeptìdeo pde8, polinucleotìdeo codificando o mesmo, dna, polinucleotìdeo anti-sentido, construção de expressão, célula hospedeira, processo para produzir um polipeptìdeo pde8, anticorpo, hibridoma, anticorpo anti-idiotipo, processo para identificar um composto parceiro de ligação espefcìfico de um polipeptìdeo pde8a, e de polinucleotìdeo pde8a, composto, e, composição.
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
Benjamin et al. Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells.
BR0308401A (pt) Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.